OWP Pharmaceuticals focuses on providing accessible pharmaceutical care through its innovative product offerings, particularly in the realm of neurological disorders. The company markets Subvenite® (lamotrigine tablets, USP), which serves as a branded generic alternative to Lamictal® (lamotrigine). These Starter Kits are designed to assist patients in initiating lamotrigine therapy, following FDA-approved titration schedules. OWP's commitment to patient care is evident in its dedication to ensuring that individuals, regardless of their circumstances, receive effective medications while also supporting humanitarian efforts through the ROW Foundation.

In addition to its product offerings, OWP Pharmaceuticals emphasizes the importance of safety and efficacy in its treatments. Subvenite is indicated for various conditions, including epilepsy and bipolar disorder, and comes with a comprehensive set of warnings and precautions regarding potential serious side effects, such as life-threatening skin rashes and hypersensitivity reactions. The company actively monitors adverse reactions and provides detailed prescribing information to healthcare providers, ensuring that patients are well-informed about the risks and benefits associated with their treatment. Through these efforts, OWP Pharmaceuticals aims to enhance the quality of life for patients while contributing to global health initiatives.

United States

OWP Pharmaceuticals provides FDA approved epilepsy medications to patients at affordable prices in the United States. We have created a business model that has a significant tie to a "Not for Profit" organization named the ROW Foundation. Through this model both organizations have a vision to drastically improve the lives of epilepsy patients throughout the world including under-resourced patients outside of the United States through increase education, diagnosis and treatment.

OWP Pharmaceuticals

Company Details